Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atea Pharmaceuticals (AVIR) Free Cash Flow (2019 - 2026)

Atea Pharmaceuticals' Free Cash Flow history spans 8 years, with the latest figure at -$46.4 million for Q1 2026.

  • Quarterly Free Cash Flow fell 51.79% to -$46.4 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$147.9 million through Mar 2026, down 17.17% year-over-year, with the annual reading at -$132.0 million for FY2025, 2.56% up from the prior year.
  • Free Cash Flow came in at -$46.4 million for Q1 2026, down from -$28.2 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of -$16.1 million in Q2 2023 to a low of -$59.7 million in Q1 2022.
  • The 5-year median for Free Cash Flow is -$29.8 million (2023), against an average of -$30.7 million.
  • The largest YoY upside for Free Cash Flow was 71.43% in 2022 against a maximum downside of 254.64% in 2022.
  • Atea Pharmaceuticals' Free Cash Flow stood at -$21.5 million in 2022, then decreased by 1.34% to -$21.8 million in 2023, then tumbled by 39.22% to -$30.4 million in 2024, then grew by 7.15% to -$28.2 million in 2025, then crashed by 64.37% to -$46.4 million in 2026.
  • Per Business Quant, the three most recent readings for AVIR's Free Cash Flow are -$46.4 million (Q1 2026), -$28.2 million (Q4 2025), and -$40.4 million (Q3 2025).